Clinical Trials Directory

Trials / Terminated

TerminatedNCT02452710

Harnessing the Effect of an Open-Label Placebo on Fatigue in Cancer Survivors

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Dana-Farber Cancer Institute · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This research study is evaluating the usefulness of a placebo (a tablet with no active ingredients) on fatigue in cancer survivors.

Detailed description

Fatigue can be a problem for some people after cancer treatment. In clinical trials, placebos (tablets with no active ingredients) have been shown to improve symptoms of some medical conditions including fatigue. This study is being done to test the usefulness of taking placebos for improving cancer-related fatigue. In this study, the investigators are testing whether symptoms of fatigue will improve when people know they are taking a tablet with no active ingredients. This is a randomized study, which means the participant will be put into one of two groups. Because no one knows which of the study options is best, the participant will be 'randomized' into one of the two study groups. Randomization means that the participant will be put into a group by chance. It is like flipping a coin. Neither the participant nor the research doctor will choose what group he or she will be in. The participant will have an equal chance of being placed in each of the groups.

Conditions

Interventions

TypeNameDescription
OTHERPlaceboOpen-label placebo

Timeline

Start date
2015-08-01
Primary completion
2017-02-01
Completion
2017-02-01
First posted
2015-05-25
Last updated
2018-12-12

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02452710. Inclusion in this directory is not an endorsement.